Literature DB >> 2879003

Adrenal catecholamine concentration after chronic treatment with bromocriptine and haloperidol.

S N Baksi, M J Hughes, H K Strahlendorf.   

Abstract

Adrenal catecholamine concentration was measured by HPLC with electrochemical detection in male rats after ten days of bromocriptine and haloperidol (0.05, 0.5 and 5.0 mg kg-1) and vehicle (1.0 ml kg-1) treatments subcutaneously. There were four rats in each group. The results indicate that bromocriptine treatment significantly increased dopamine (DA), noradrenaline (NA) and adrenaline (A) content in a dose-dependent manner. The NA/DA ratio was unchanged, but the A/NA ratio was significantly increased after treatments with two higher doses of the drug. Haloperidol treatment, on the other hand, had no significant effect on dopamine and a biphasic effect on adrenaline content. Noradrenaline concentration increased only after the lowest dose of the drug. There was no significant change in NA/DA or A/NA ratios in any group. The dopamine metabolite, dihydroxyphenylacetic acid (DOPAC), was not detected in any adrenal gland.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2879003     DOI: 10.1111/j.2042-7158.1986.tb04491.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  1 in total

1.  Enhancement of dopaminergic agonist bromocriptine of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.

Authors:  H Iishi; M Baba; M Tatsuta; S Okuda; H Taniguchi
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.